Quarterly report pursuant to Section 13 or 15(d)

Loss per Share

v3.8.0.1
Loss per Share
9 Months Ended
Sep. 30, 2017
Loss per Share
11. Loss per Share

The computation of basic and diluted net income (loss) per share for the periods indicated is as follows:

 

    

Three Months Ended

September 30,

    

Nine Months Ended

September 30,

 
     2017      2016      2017      2016  

Numerator:

           

Net income (loss)

   $ (2.5    $ 1.6      $ (8.2    $ (2.1
  

 

 

    

 

 

    

 

 

    

 

 

 

Denominator:

           

Weighted-average common shares (in thousands) - basic

     20,936        20,491        20,766        18,519  

Effect of restricted shares

     —          385        —          —    

Effect of restricted share units

     —          11        —          —    

Effect of contingent purchase price obligations

     —          256        —          —    
  

 

 

    

 

 

    

 

 

    

 

 

 

Weighted-average common shares (in thousands) - diluted

     20,936        21,143        20,766        18,519  
  

 

 

    

 

 

    

 

 

    

 

 

 

Basic and diluted net income (loss) per share

   $ (0.12    $ 0.08      $ (0.39    $ (0.11
  

 

 

    

 

 

    

 

 

    

 

 

 

Included in the computation of basic net loss per share for the three and nine months ended September 30, 2017 and 2016 were 13,333 and 66,668 potentially dilutive shares, respectively.

Additionally, at September 30, 2017 and 2016, we were contingently obligated to pay $0.2 million and $1.6 million, which may be settled, at our option, in either cash or an equivalent amount of common shares based upon their then-current market value, if certain performance criteria had been met. The equivalent amount of common shares have been excluded from the computation of diluted net loss per share for the three and nine months ended September 30, 2017 and 2016, as they were antidilutive.

At September 30, 2017 and 2016, 24,928 and 27,828 outstanding options, respectively, with an average exercise price of $44.45 and $44.76, respectively, were not recognized in the diluted earnings per share calculation as they were antidilutive.